Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

1 clinical trial, the results of nonclinical mouse studies of Vaxfectin(R)-formulated protein-based influenza vaccines, and the results of a nonclinical mouse study of a Vaxfectin(R)-formulated TRP-2 peptide cancer vaccine. Risks and uncertainties include whether H5N1 influenza DNA vaccine Phase 1 clinical trial results will be confirmed in larger studies; whether nonclinical results from mouse studies will advance to human clinical testing, and if so, whether such testing will yield similar results; whether DNA vaccines against H5N1 influenza or any other targets will be successfully developed and commercialized; whether DNA vaccines will become alternatives to conventional vaccines; whether Vical or others will secure funding to advance the pandemic influenza DNA vaccine program; whether commercial partners or collaborators will pursue additional Vaxfectin(R) applications; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Heidi Chokeir, Ph.D., or David Schull

Vical Incorporated Russo Partners

(858) 646-1127 (619) 814-3512

aengbring@vical.com heidi.chokeir@russopartnersllc.com

Website: http://www.vical.com '/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, Inc., ... treatment of cancer, today announced that Rachel ... company,s Board of Directors, has been appointed chief ... Eli Lilly and AstraZeneca, and also oversaw clinical ... checkpoint inhibitor, at Bristol-Myers Squibb and the development ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015 Oryzon today ... Renshaw 17th Annual Global Investment Conference in New ... ORYZON will be represented by President and CEO Carlos ... Dr. Buesa will present this information on Thursday September 10, ... Floor).  The company is completing preclinical development of its ORY-2001 ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... to Educate Women About this Common Condition, MILWAUKEE, ... at the Hyatt Regency Milwaukee hotel (333 West Kilbourn ... 7:30 pm to talk about her,experience with stress urinary ... Down There?: Breaking the Ice About SUI, a,national public ...
... Opiate-Like Side Effects For Several ... Months Following a Single Administration, SOUTH SAN FRANCISCO, Calif., ... that it has initiated a new,Phase 2 study of Adlea(TM) ... total knee replacement surgery, also called,total knee arthroplasty (TKA). Adlea ...
Cached Medicine Technology:Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 2Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 2Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 4
(Date:8/27/2015)... Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Association and the American Heart Association have released new guidelines to educate doctors and ... the last update to these particular guidelines came in 2007, so the new version ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Thriveology Founders, ... the featured speakers at The Amazing Aging Expo in Denver, Colorado on Saturday, August ... doctors are consistently featured in media outlets as health authorities, and will present a ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... the exploding legal marijuana industry with the launch of its Doobster platform, a ... marijuana to order products from their smart phones and tablets. Well, Doobster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of mothers ... Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and causing ... University study. , While most people don’t develop persistent depression after a major ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... ... in Ophthalmology (JCAHPO), and the Association of Technical Personnel in Ophthalmology (ATPO) proudly launched ... Reference Guide for the Ophthalmic Technician. , ... St. Paul, MN (Vocus) November 10, 2009 -- Compact, ...
... HATBORO, Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: ... solutions for the healthcare and commercial industries, today announced ... exception to NASDAQ,s stockholder approval requirements, in accordance with ... on this exception to complete a proposed plan of ...
... ... Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, 2009 -- The Andrews-Paulos Research & ... Rounds presentation on November, 19, 2009 at 5:30 p.m. (CT). Renowned orthopaedic and sports ...
... Better coordination urged to stem re-admission rate of nearly 1 ... Almost a quarter of the people on Medicare who are ... a month of discharge, a new study reveals. , That ... assistant professor of geriatrics and palliative medicine at the Mount ...
... YORK Medications frequently given to cancer patients to ... increased risk of deep vein thrombosis or pulmonary embolism, ... M.S., co-director of the breast cancer program at the ... Medical Center. The findings will be published online on ...
... Amalgamated Capital, a newly formed division of Amalgamated ... in the recapitalization of Oklahoma City-based 180 Medical, Inc., ... Amalgamated Capital provides senior cash flow debt financing to ... firms and other investors are financial sponsors. , 180 ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:The Revolving Door of Heart Failure Hospitalization 2Health News:The Revolving Door of Heart Failure Hospitalization 3Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 2Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 2Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: